Physician profile
Charles E Johnson
NPI 1285675835
$1,361.79
in general payments reported to CMS, 2019-2025
16 companies · $80.83 in 2025
The $80.83 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $42.51 · 2021: $156 · 2022: $466 · 2023: $107 · 2024: $379 · 2025: $80.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.14 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.28 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $87.50 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $73.49 | 2020-2024 | Entyvio |
| Evoke Pharma, INC. | $67.89 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.34 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $44.75 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $39.73 | 2024 | |
| Ironwood Pharmaceuticals, INC | $36.34 | 2023-2024 | Linzess |
| Lilly USA, LLC | $33.55 | 2024 | Omvoh |
| Celgene Corporation | $30.21 | 2022 | |
| Gilead Sciences, INC. | $26.17 | 2023 | |
| Pfizer INC. | $23.42 | 2022 | |
| Olympus America INC. | $22.51 | 2025 | Gastrointestinal Videoscope |
| Redhill Biopharma INC. | $16.76 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.